{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:53:20Z","timestamp":1788292400989,"version":"build-2803163510"},"reference-count":34,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Synnovis Innovation Accelerator Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Surveillance of non-muscle-invasive bladder cancer (NMIBC) relies on cystoscopy and urine cytology, both of which have well-recognised limitations. Molecular urine assays have been developed to reduce the burden of invasive surveillance, yet their real-world clinical utility remains uncertain. Uromonitor\u00ae is a quantitative PCR-based assay targeting hotspot variants in the TERT promoter, FGFR3, and KRAS, which are frequently altered in urothelial carcinoma. We evaluated the performance of Uromonitor\u00ae in routine clinical practice and assessed its technical reproducibility. Methods: Uromonitor\u00ae diagnostic test accuracy was retrospectively calculated from samples from patients undergoing investigation for suspected bladder cancer (n = 64) or surveillance (n = 30) following a prior diagnosis at a tertiary referral centre between 2021 and 2023. Uromonitor\u00ae results were compared with histology where available (n = 49, 52%), or with contemporaneous cystoscopy and urine cytology findings (n = 45, 48%). This pragmatic dual reference standard reflects routine clinical practice but may introduce some heterogeneity in diagnostic accuracy verification. A prospective in-house verification cohort was used to assess inter-laboratory reproducibility. Discordant cases underwent orthogonal next-generation sequencing (NGS) analysis. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy were calculated for the Uromonitor\u00ae against the standard of care. Results: Ninety-four patients were included in the clinical performance analysis. Overall sensitivity, specificity, PPV, NPV and overall accuracy for Uromonitor\u00ae were 38%, 88%, 63%, 72% and 70%, respectively. Sensitivity was higher in the diagnostic setting (47%; 95% CI 27.3\u201368.3%) than during surveillance (23%; 95% CI 8.2\u201350.2%). Several false-negative cases in the verification cohort harboured variants either detectable by NGS at variant allele frequencies below or slightly above the assay\u2019s limit of detection or variants not covered by the assay hotspot design. Inter-laboratory reproducibility was excellent, with 100% concordance observed in the verification cohort. Conclusions: In a real-world clinical setting, Uromonitor\u00ae demonstrated high specificity but limited sensitivity for detection of bladder cancer, particularly during surveillance. A negative result does not reliably exclude recurrence. Assay sensitivity thresholds and restricted variant coverage appear to be key contributors to false-negative results. These findings highlight the need for cautious clinical integration of Uromonitor\u00ae. It is unclear whether this approach has sufficient sensitivity in surveillance to safely reduce cystoscopy frequency. This underscores the need for further refinement of urine-based molecular assays, including a need for enhanced sensitivity and broader mutational coverage before routine clinical adoption.<\/jats:p>","DOI":"10.3390\/cancers18101650","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T09:12:41Z","timestamp":1779268361000},"page":"1650","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Evaluation of Uromonitor\u00ae for Bladder Cancer Detection and Surveillance"],"prefix":"10.3390","volume":"18","author":[{"given":"Amy","family":"Newman","sequence":"first","affiliation":[{"name":"Cancer Genetics, Guy\u2019s Hospital, Synnovis, London SE1 9RT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha","family":"Hansel","sequence":"additional","affiliation":[{"name":"Cancer Genetics, Guy\u2019s Hospital, Synnovis, London SE1 9RT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Gerrard","sequence":"additional","affiliation":[{"name":"Cancer Genetics, Guy\u2019s Hospital, Synnovis, London SE1 9RT, UK"},{"name":"Guy\u2019s Hospital, GSTT NHS Foundation Trust, London SE1 7EH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8578-2296","authenticated-orcid":false,"given":"Llwyd","family":"Orton","sequence":"additional","affiliation":[{"name":"Neurophysiology, Manchester Metropolitan University, Manchester M15 6BX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Chandra","sequence":"additional","affiliation":[{"name":"Guy\u2019s Hospital, GSTT NHS Foundation Trust, London SE1 7EH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Nair","sequence":"additional","affiliation":[{"name":"Guy\u2019s Hospital, GSTT NHS Foundation Trust, London SE1 7EH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3865-5988","authenticated-orcid":false,"given":"Francesco","family":"Del Giudice","sequence":"additional","affiliation":[{"name":"Department of Maternal-Infant and Urological Sciences, \u201cSapienza\u201d University of Rome, Umberto I Hospital, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Guy\u2019s Hospital, GSTT NHS Foundation Trust, London SE1 7EH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsie","family":"Mensah","sequence":"additional","affiliation":[{"name":"Guy\u2019s Hospital, GSTT NHS Foundation Trust, London SE1 7EH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shamim","family":"Khan","sequence":"additional","affiliation":[{"name":"Guy\u2019s Hospital, GSTT NHS Foundation Trust, London SE1 7EH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Thurairaja","sequence":"additional","affiliation":[{"name":"Guy\u2019s Hospital, GSTT NHS Foundation Trust, London SE1 7EH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Abu Ghanem","sequence":"additional","affiliation":[{"name":"Guy\u2019s Hospital, GSTT NHS Foundation Trust, London SE1 7EH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.eururo.2023.03.029","article-title":"Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors","volume":"84","author":"Jubber","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology Guidelines on Non-Muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)\u20142019 Update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.urolonc.2020.08.016","article-title":"Urinary Biomarkers in Bladder Cancer: A Review of the Current Landscape and Future Directions","volume":"39","author":"Ng","year":"2021","journal-title":"Urol. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.euo.2021.10.003","article-title":"Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis","volume":"4","author":"Laukhtina","year":"2021","journal-title":"Eur. Urol. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"922","DOI":"10.7326\/M15-0997","article-title":"Urinary Biomarkers for Diagnosis of Bladder Cancer: A Systematic Review and Meta-analysis","volume":"163","author":"Chou","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1097\/PAS.0000000000002053","article-title":"International Society of Urological Pathology Consensus Conference on Current Issues in Bladder Cancer. Working Group 4: Molecular Subtypes of Bladder Cancer\u2014Principles of Classification and Emerging Clinical Utility","volume":"48","author":"Warrick","year":"2024","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_8","first-page":"101448","article-title":"Relationship Between Variantal Landscape and Clinical Characteristics of Bladder Cancer","volume":"22","author":"Guo","year":"2022","journal-title":"Transl. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1158\/0008-5472.CAN-03-2421","article-title":"FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma","volume":"64","author":"Vis","year":"2004","journal-title":"Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"7401","DOI":"10.1158\/0008-5472.CAN-06-1182","article-title":"PIK3CA variants are an early genetic alteration associated with FGFR3 variants in superficial papillary bladder tumors","volume":"66","author":"Malats","year":"2006","journal-title":"Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Batista, R., Vinagre, J., Prazeres, H., Sampaio, C., Peralta, P., Concei\u00e7\u00e3o, P., Sismeiro, A., Le\u00e3o, R., Gomes, A., and Furriel, F. (2019). Validation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence Surveillance of Patients With Non-Muscle-Invasive Bladder Cancer in a Comprehensive Multicenter Study. Front. Genet., 10.","DOI":"10.3389\/fgene.2019.01237"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Sieverink, C.A., Batista, R.P.M., Prazeres, H.J.M., Vinagre, J., Sampaio, C., Le\u00e3o, R.R., M\u00e1ximo, V., Witjes, J.A., and Soares, P. (2020). Clinical Validation of a Urine Test (Uromonitor-V2\u00ae) for the Surveillance of Non-Muscle-Invasive Bladder Cancer Patients. Diagnostics, 10.","DOI":"10.3390\/diagnostics10100745"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Azawi, N.H., Lommer, N., Nymann Baunwall, S.M., Byrjalsen, A., Fode, M., Pedersen, A.J., and Bjerklund Johansen, T.E. (2023). Surveillance of Low-Grade Non-Muscle Invasive Bladder Tumors Using Uromonitor: SOLUSION Trial. Cancers, 15.","DOI":"10.3390\/cancers15082341"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/bju.16450","article-title":"Real-world Performance of Uromonitor\u00ae in Urothelial Bladder Cancer Detection: A Multicentric Trial","volume":"134","author":"Wolff","year":"2024","journal-title":"BJU Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/bju.70010","article-title":"External validation of the Uromonitor\u00ae-version 2 urine test as a biomarker for optimisation of non-muscle-invasive bladder cancer management","volume":"137","author":"Alcaraz","year":"2026","journal-title":"BJU Int."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/PAP.0000000000000118","article-title":"The Paris System for Reporting Urinary Cytology: The Quest to Develop a Standardized Terminology","volume":"23","author":"Barkan","year":"2016","journal-title":"Adv. Anat. Pathol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Moch, H., Humphrey, P.A., Ulbright, T.M., and Reuter, V.E. (2016). WHO Classification of Tumours of the Urinary System and Male Genital Organs, International Agency for Research on Cancer. [4th ed.].","DOI":"10.1016\/j.eururo.2016.02.028"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Brierley, J.D., Gospodarowicz, M.K., and Wittekind, C. (2017). TNM Classification of Malignant Tumours, Wiley-Blackwell. [8th ed.].","DOI":"10.1002\/9780471420194.tnmc26.pub3"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ccell.2017.08.005","article-title":"Genomic Subtypes of Non-invasive Bladder Cancer with Distinct Metabolic Profile and Female Gender Bias in KDM6A Variant Frequency","volume":"32","author":"Hurst","year":"2017","journal-title":"Cancer Cell."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","article-title":"Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets","volume":"72","author":"Pietzak","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_21","unstructured":"Uromonitor\u00ae (2022). Performance Validation Report, U-Monitor."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E","article-title":"Two-sided Confidence Intervals for the Single Proportion: Comparison of Seven Methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Ruiz-Villalba, A., Ruijter, J.M., and van den Hoff, M.J.B. (2021). Use and Misuse of Cq in qPCR Data Analysis and Reporting. Life, 11.","DOI":"10.3390\/life11060496"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jmoldx.2017.01.011","article-title":"Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists","volume":"19","author":"Jennings","year":"2017","journal-title":"J. Mol. Diagn."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1126\/science.aba7300","article-title":"Macroscopic somatic clonal expansion in morphologically normal human urothelium","volume":"370","author":"Li","year":"2020","journal-title":"Science"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/labinvest.2008.27","article-title":"Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy","volume":"88","author":"Majewski","year":"2008","journal-title":"Lab. Invest."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1146\/annurev-pathol-012513-104703","article-title":"Origins of Bladder Cancer","volume":"11","author":"Czerniak","year":"2016","journal-title":"Annu. Rev. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.urology.2006.03.062","article-title":"Clinical model of lifetime cost of treating bladder cancer and associated complications","volume":"68","author":"Avritscher","year":"2006","journal-title":"Urology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/MOU.0000000000000078","article-title":"The burden of bladder cancer care: Direct and indirect costs","volume":"24","author":"Mossanen","year":"2014","journal-title":"Curr. Opin. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.euo.2019.01.015","article-title":"The Cost to Medicare of Bladder Cancer Care","volume":"3","author":"Sloan","year":"2020","journal-title":"Eur. Urol. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3233\/BLC-230096","article-title":"Noninvasive Tests for Bladder Cancer Detection and Surveillance: A Systematic Review of Commercially Available Assays","volume":"10","author":"Heard","year":"2024","journal-title":"Bladder Cancer"},{"key":"ref_32","first-page":"S247","article-title":"Urinary biomarkers in bladder cancer: Where do we stand?","volume":"8","author":"Vasdev","year":"2019","journal-title":"Transl. Androl. Urol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/bju.14808","article-title":"Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: A 23-gene panel with utility for non-invasive diagnosis and risk stratification","volume":"124","author":"Ward","year":"2019","journal-title":"BJU Int."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Hayashi, Y., Fujita, K., Matsuzaki, K., Eich, M.L., Tomiyama, E., Matsushita, M., Koh, Y., Nakano, K., Wang, C., and Ishizuya, Y. (2020). Clinical Significance of Hotspot Variant Analysis of Urinary Cell-Free DNA in Urothelial Bladder Cancer. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00755"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/10\/1650\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T09:38:48Z","timestamp":1779269928000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/10\/1650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":34,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["cancers18101650"],"URL":"https:\/\/doi.org\/10.3390\/cancers18101650","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]}}}